Video

Dr. Hoshida on Molecular Subtyping in HCC

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

Yujin Hoshida, MD, PhD, associate professor of internal medicine, University of Texas Southwestern Medical Center, discusses molecular subtyping in hepatocellular carcinoma (HCC).

Over the past decade, multiple subtypes of HCC have been identified using advanced genomic technology, says Hoshida. The research suggests that there may be a link between how patients with different molecular subtypes of HCC respond to different therapeutic options, explains Hoshida.

Understanding what patient subtype responds best to what treatment may be a more efficient way to personalize therapy rather than to direct specific drugs to multiple targets, concludes Hoshida.

Related Videos
Suneel Kamath, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Kevin Kalinsky, MD, MS
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD